193 related articles for article (PubMed ID: 14697927)
21. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.
Lebranchu Y; Bridoux F; Büchler M; Le Meur Y; Etienne I; Toupance O; Hurault de Ligny B; Touchard G; Moulin B; Le Pogamp P; Reigneau O; Guignard M; Rifle G
Am J Transplant; 2002 Jan; 2(1):48-56. PubMed ID: 12095056
[TBL] [Abstract][Full Text] [Related]
22. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
23. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
[TBL] [Abstract][Full Text] [Related]
24. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
[TBL] [Abstract][Full Text] [Related]
25. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period.
Balbontin F; Kiberd B; Fraser A; Kiberd M; Lawen J
Clin Transplant; 2005 Apr; 19(2):225-9. PubMed ID: 15740559
[TBL] [Abstract][Full Text] [Related]
26. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial.
Arbogast HP; Hoffmann JN; Illner WD; Hillebrand GF; Fischereder M; Jauch KW; Land W
Transplant Proc; 2009; 41(6):2529-32. PubMed ID: 19715968
[TBL] [Abstract][Full Text] [Related]
27. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
Kovac D; Kotnik V; Kandus A
Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
[TBL] [Abstract][Full Text] [Related]
28. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
29. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
30. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
31. Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol.
Rahamimov R; Yussim A; After T; Lustig S; Bar-Nathan N; Shaharabani E; Shapira Z; Shabthai E; Mor E
Transplant Proc; 2003 Mar; 35(2):653-4. PubMed ID: 12644082
[No Abstract] [Full Text] [Related]
32. Kidney graft outcomes in living-related transplantation have improved with substitution of basiliximab and mycophenolate mofetil for antithymocyte globulin and azathioprine: a single center retrospective cohort study.
Imamović G; Zerem E; Osmanović E
Eur J Intern Med; 2010 Dec; 21(6):524-9. PubMed ID: 21111938
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
[TBL] [Abstract][Full Text] [Related]
35. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
Jorge S; Guerra J; Silva S; Santana A; Mil-Homens C; Prata MM
Transplant Proc; 2008 Apr; 40(3):693-6. PubMed ID: 18454989
[TBL] [Abstract][Full Text] [Related]
36. Recovery of graft function in pediatric kidney transplantation is not affected by delayed introduction of cyclosporine.
Cransberg K; Bouts AH; Cornelissen EA; Lilien MR; Van Hoeck KJ; Hop WC; Nauta J
Transplantation; 2008 Nov; 86(9):1199-205. PubMed ID: 19005400
[TBL] [Abstract][Full Text] [Related]
37. Initial immunosuppression with or without basiliximab: a comparative study.
Martín-Mateos RM; Graus J; Albillos A; Arocena C; Rodríguez Gandía MA; Blesa C; García-Hoz F; García González M; García-Alonso FJ; Bárcena R
Transplant Proc; 2012 Nov; 44(9):2570-2. PubMed ID: 23146457
[TBL] [Abstract][Full Text] [Related]
38. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
40. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Mycophenolate Mofetil Acute Renal Rejection Study Group
Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
